Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): Modifications of technique and impact on ejaculation

J. P. Donohue, J. A. Thornhill, R. S. Foster, R. G. Rowland, R. Bihrle

Research output: Contribution to journalArticle

223 Scopus citations

Abstract

Results with primary retroperitoneal lymphadenectomy in 464 patients with clinical stage A nonseminomatous germ cell testis cancer (1965 to 1989) were reviewed. The false-negative staging error by clinical methods remains at 30%. The relapse rate in pathological stage A cancer patients was 11% (37 of 323), with 2 deaths. For pathological stage B disease 64% of the patients were cured by retroperitoneal lymphadenectomy alone. With modern adjuvant chemotherapy no stage B tumor relapsed since 1979 and the survival rate was 100%. For all 25 years (464 patients) the relapse rate was 14% and the survival rate was 98.9% (3 cancer and 2 noncancer deaths). Because these results are based on preoperative clinical staging, they are directly comparable with series using radiotherapy or surveillance.

Original languageEnglish (US)
Pages (from-to)237-243
Number of pages7
JournalJournal of Urology
Volume149
Issue number2
DOIs
StatePublished - Jan 1 1993

    Fingerprint

Keywords

  • ejaculation
  • lymph node excision
  • retroperitoneal space
  • testicular neoplasms

ASJC Scopus subject areas

  • Urology

Cite this